<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39378280</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2162-3279</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Brain and behavior</Title><ISOAbbreviation>Brain Behav</ISOAbbreviation></Journal><ArticleTitle>High Somatization Rates, Frequent Spontaneous Recovery, and a Lack of Organic Biomarkers in Post-Covid-19 Condition.</ArticleTitle><Pagination><StartPage>e70087</StartPage><MedlinePgn>e70087</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70087</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/brb3.70087</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Many patients report neuropsychiatric symptoms after SARS-CoV-2 infection. Data on prevalence of post-COVID-19 condition (PCC) vary due to the lack of specific diagnostic criteria, the report of unspecific symptoms, and reliable biomarkers.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PCC patients seen in a neurological outpatient department were followed for up to 18 months. Neurological examination, SARS-CoV-2 antibodies, Epstein-Barr virus antibodies, and cortisol levels as possible biomarkers, questionnaires to evaluate neuropsychiatric symptoms and somatization (Patient Health Questionnaires D [PHQ-D]), cognition deficits (Montreal Cognitive Assessment [MoCA]), sleep disorders (ISS, Epworth Sleepiness Scale [ESS]), and fatigue (FSS) were included.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 175 consecutive patients (78% females, median age 42 years) were seen between May 2021 and February 2023. Fatigue, subjective stress intolerance, and subjective cognitive deficits were the most common symptoms. Specific scores were positive for fatigue, insomnia, and sleepiness and were present in 95%, 62.1%, and 44.0%, respectively. Cognitive deficits were found in 2.3%. Signs of somatization were identified in 61%, who also had an average of two symptoms more than patients without somatization. Overall, 28% had a psychiatric disorder, including depression and anxiety. At the second visit (n = 92), fatigue (67.3%) and insomnia (45.5%) had decreased. At visit three (n = 43), symptom load had decreased in 76.8%; overall, 51.2% of patients were symptom-free. Biomarker testing did not confirm an anti-EBV response. SARS-CoV-2-specific immune reactions increased over time, and cortisol levels were within the physiological range.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite high initial symptom load, 76.8% improved over time. The prevalence of somatization and psychiatric disorders was high. Our data do not confirm the role of previously suggested biomarkers in PCC patients.</AbstractText><CopyrightInformation>© 2024 The Author(s). Brain and Behavior published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tröscher</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3003-4677</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebetsroither</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rindler</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Böhm</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dormann</LastName><ForeName>Rainer</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Oertzen</LastName><ForeName>Tim</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-2164-7842</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Directorate, University Hospital Würzburg, Würzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heidbreder</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helbok</LastName><ForeName>Raimund</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Evangelisches Klinikum Gelsenkirchen, Academic Hospital University Essen-Duisburg, Gelsenkirchen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Service Center for Clinical Research of the Kepler University Hospital</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Brain Behav</MedlineTA><NlmUniqueID>101570837</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013001" MajorTopicYN="Y">Somatoform Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007319" MajorTopicYN="N">Sleep Initiation and Maintenance Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EBV reactivation</Keyword><Keyword MajorTopicYN="N">brain fog</Keyword><Keyword MajorTopicYN="N">post‐Covid</Keyword><Keyword MajorTopicYN="N">post‐acute sequelae of COVID‐19 (PASC)</Keyword></KeywordList><CoiStatement>Judith Wagner received speaker fees from Janssen‐Cilag GmbH, UCB Pharma AG, Boehringer Ingelheim, congress/travel funds from Novartis Pharma GmbH, Roche Austria GmbH, Boehringer Ingelheim, and added board reimbursements from Janssen‐Cilag GmbH and Novartis Pharma GmbH. Vincent Böhm received travel funds from Novartis Pharma GmbH. Tim von Oertzen received grants from FFG and Böhringer Ingelheim, consulting fees or honoraria for lectures from Angelini Pharma, Arvelle, GW Pharma, Jazz Pharma, Biogen, LivaNova plc and Eisai, travel and meeting support from Angelini Pharma and Jazz Pharma. All other authors report no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>22</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39378280</ArticleId><ArticleId IdType="pmc">PMC11460636</ArticleId><ArticleId IdType="doi">10.1002/brb3.70087</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altmann, D. M. , Whettlock E. M., Liu S., Arachchillage D. J., and Boyton R. J.. 2023. “The Immunology of Long COVID.” Nature Reviews Immunology 23, no. 10: 618–634. 10.1038/s41577-023-00904-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00904-7</ArticleId><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz, R. , Siles N., Kelley M., Wylie D., Melamed E., and Brode W. M.. 2023. “Clinical Characteristics of Long COVID Patients Presenting to a Dedicated Academic Post‐COVID‐19 Clinic in Central Texas.” Scientific Reports 13, no. 1: 1–9. 10.1038/s41598-023-48502-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-48502-w</ArticleId><ArticleId IdType="pmc">PMC10713530</ArticleId><ArticleId IdType="pubmed">38081885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball, H. A. , Mcwhirter L., Ballard C., et al. 2020. “Functional Cognitive Disorder: Dementia's Blind Spot.” Brain 143, no. 10: 2895–2903. 10.1093/BRAIN/AWAA224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/BRAIN/AWAA224</ArticleId><ArticleId IdType="pmc">PMC7586080</ArticleId><ArticleId IdType="pubmed">32791521</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker, J. H. , Lin J. J., Doernberg M., et al. 2021. “Assessment of Cognitive Function in Patients After COVID‐19 Infection.” JAMA Network Open 4, no. 10: e2130645–e2130645. 10.1001/JAMANETWORKOPEN.2021.30645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMANETWORKOPEN.2021.30645</ArticleId><ArticleId IdType="pmc">PMC8536953</ArticleId><ArticleId IdType="pubmed">34677597</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg, B. , Mohn K. G.‐I., Brokstad K. A., et al. 2021. “Long COVID in a Prospective Cohort of Home‐Isolated Patients.” Nature Medicine 27: 1607–1613. 10.1038/s41591-021-01433-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Casjens, S. , Taeger D., Brüning T., and Behrens T.. 2024. “Changes in Mental Distress Among Employees During the Three Years of the COVID‐19 Pandemic in Germany.” PLoS ONE 19, no. 5: e0302020. 10.1371/JOURNAL.PONE.0302020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PONE.0302020</ArticleId><ArticleId IdType="pmc">PMC11068204</ArticleId><ArticleId IdType="pubmed">38701106</ArticleId></ArticleIdList></Reference><Reference><Citation>Crivelli, L. , Palmer K., Calandri I., et al. 2022. “Changes in Cognitive Functioning After COVID‐19: A Systematic Review and Meta‐Analysis.” Alzheimer's &amp; Dementia : The Journal of the Alzheimer's Association 18, no. 5: 1047–1066. 10.1002/ALZ.12644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ALZ.12644</ArticleId><ArticleId IdType="pmc">PMC9073922</ArticleId><ArticleId IdType="pubmed">35297561</ArticleId></ArticleIdList></Reference><Reference><Citation>Du, M. , Ma Y., Deng J., Liu M., and Liu J.. 2022. “Comparison of Long COVID‐19 Caused by Different SARS‐CoV‐2 Strains: A Systematic Review and Meta‐Analysis.” International Journal of Environmental Research and Public Health 19, no. 23: 16010. 10.3390/IJERPH192316010/S1.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/IJERPH192316010/S1</ArticleId><ArticleId IdType="pmc">PMC9736973</ArticleId><ArticleId IdType="pubmed">36498103</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleischer, M. , Szepanowski F., Tovar M., et al. 2022. “Post‐COVID‐19 Syndrome Is Rarely Associated With Damage of the Nervous System: Findings From a Prospective Observational Cohort Study in 171 Patients.” Neurology and Therapy 11, no. 4: 1637–1657. 10.1007/S40120-022-00395-Z/FIGURES/5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S40120-022-00395-Z/FIGURES/5</ArticleId><ArticleId IdType="pmc">PMC9417089</ArticleId><ArticleId IdType="pubmed">36028604</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler, C. , Wang Z., Lorenzi J. C. C., et al. 2021. “Evolution of Antibody Immunity to SARS‐CoV‐2.” Nature 591, no. 7851: 639–644. 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandjour, A. 2023. “Long COVID: Costs for the German Economy and Health Care and Pension System.” BMC Health Services Research 23, no. 1: 1–7. 10.1186/S12913-023-09601-6/TABLES/1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12913-023-09601-6/TABLES/1</ArticleId><ArticleId IdType="pmc">PMC10266873</ArticleId><ArticleId IdType="pubmed">37316880</ArticleId></ArticleIdList></Reference><Reference><Citation>Giussani, G. , Westenberg E., Garcia‐Azorin D., et al. 2024. “Prevalence and Trajectories of Post‐COVID‐19 Neurological Manifestations: A Systematic‐Review and Meta‐Analysis.” Neuroepidemiology 58: 120–133. 10.1159/000536352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000536352</ArticleId><ArticleId IdType="pubmed">38272015</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold, J. E. , Okyay R. A., Licht W. E., and Hurley D. J.. 2021. “Investigation of Long COVID Prevalence and Its Relationship to Epstein‐Barr Virus Reactivation.” Pathogens 10, no. 6: 763. 10.3390/PATHOGENS10060763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/PATHOGENS10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Gräfe, K. , Zipfel S., Herzog W., and Löwe B.. 2004. “Screening Psychischer Störungen Mit Dem “Gesundheitsfragebogen Für Patienten (PHQ‐D)”.” Diagnostica 50, no. 4: 171–181. 10.1026/0012-1924.50.4.171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1026/0012-1924.50.4.171</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham, E. L. , Clark J. R., Orban Z. S., et al. 2021. “Persistent Neurologic Symptoms and Cognitive Dysfunction in Non‐Hospitalized Covid‐19 “Long Haulers”.” Annals of Clinical and Translational Neurology 8, no. 5: 1073–1085. 10.1002/acn3.51350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51350</ArticleId><ArticleId IdType="pmc">PMC8108421</ArticleId><ArticleId IdType="pubmed">33755344</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess, R. D. 2004. “Routine Epstein‐Barr Virus Diagnostics From the Laboratory Perspective: Still Challenging After 35 Years.” Journal of Clinical Microbiology 42, no. 8: 3381–3387. 10.1128/JCM.42.8.3381-3387.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.42.8.3381-3387.2004</ArticleId><ArticleId IdType="pmc">PMC497621</ArticleId><ArticleId IdType="pubmed">15297472</ArticleId></ArticleIdList></Reference><Reference><Citation>Høeg, T. B. , Ladhani S., and Prasad V.. 2023. “How Methodological Pitfalls Have Created Widespread Misunderstanding About Long COVID.” BMJ Evidence‐Based Medicine 29: 142–146. 10.1136/BMJEBM-2023-112338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJEBM-2023-112338</ArticleId><ArticleId IdType="pmc">PMC11137465</ArticleId><ArticleId IdType="pubmed">37748921</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeggerl, A. D. , Nunhofer V., Lauth W., et al. 2023. “Epstein‐Barr Virus Reactivation Is Not Causative for Post‐COVID‐19‐Syndrome in Individuals With Asymptomatic or Mild SARS‐CoV‐2 Disease Course.” BMC Infectious Diseases 23, no. 1: 1–13. 10.1186/S12879-023-08820-W/TABLES/1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12879-023-08820-W/TABLES/1</ArticleId><ArticleId IdType="pmc">PMC10652630</ArticleId><ArticleId IdType="pubmed">37968601</ArticleId></ArticleIdList></Reference><Reference><Citation>Horn, M. , Wathelet M., Amad A., et al. 2023. “Persistent Physical Symptoms After COVID‐19 Infection and the Risk of Somatic Symptom Disorder.” Journal of Psychosomatic Research 166: 111172. 10.1016/J.JPSYCHORES.2023.111172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JPSYCHORES.2023.111172</ArticleId><ArticleId IdType="pmc">PMC9876030</ArticleId><ArticleId IdType="pubmed">36736191</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C. , Huang L., Wang Y., et al. 2021. “6‐Month Consequences of COVID‐19 in Patients Discharged From Hospital: A Cohort Study.” Lancet 397, no. 10270: 220–232. 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>
ICD
. 2019. “ICD‐10 Version: 2019.” Accessed August 20, 2024. https://icd.who.int/browse10/2019/en#/F45.0.</Citation></Reference><Reference><Citation>Joffe, A. R. , and Elliott A.. 2023. “Long COVID as a Functional Somatic Symptom Disorder Caused by Abnormally Precise Prior Expectations During Bayesian Perceptual Processing: A New Hypothesis and Implications for Pandemic Response.” SAGE Open Medicine 11: 1–29. 10.1177/20503121231194400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20503121231194400</ArticleId><ArticleId IdType="pmc">PMC10467233</ArticleId><ArticleId IdType="pubmed">37655303</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns, M. W. 1991. “A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale.” Sleep 14, no. 6: 540–545. 10.1093/SLEEP/14.6.540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/SLEEP/14.6.540</ArticleId><ArticleId IdType="pubmed">1798888</ArticleId></ArticleIdList></Reference><Reference><Citation>Kachaner, A. , Lemogne C., Dave J., Ranque B., De Broucker T., and Meppiel E.. 2022. “Somatic Symptom Disorder in Patients With Post‐COVID‐19 Neurological Symptoms: A Preliminary Report From the Somatic Study (Somatic Symptom Disorder Triggered by COVID‐19).” Journal of Neurology, Neurosurgery &amp; Psychiatry 93, no. 11: 1174–1180. 10.1136/JNNP-2021-327899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/JNNP-2021-327899</ArticleId><ArticleId IdType="pubmed">36008115</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlert, C. R. , Strahm C., Güsewell S., et al. 2023. “Post‐Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross‐Sectional Study.” Clinical Infectious Diseases 77, no. 2: 194–202. 10.1093/CID/CIAD143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/CID/CIAD143</ArticleId><ArticleId IdType="pmc">PMC10371307</ArticleId><ArticleId IdType="pubmed">36905145</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerksieck, P. , Ballouz T., Haile S. R., et al. 2023. “Post COVID‐19 Condition, Work Ability and Occupational Changes in a Population‐Based Cohort.” Lancet Regional Health—Europe 31: 100671. 10.1016/j.lanepe.2023.100671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100671</ArticleId><ArticleId IdType="pmc">PMC10287546</ArticleId><ArticleId IdType="pubmed">37366496</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, Y. , Bae S., Chang H. H., and Kim S. W.. 2023. “Long COVID Prevalence and Impact on Quality of Life 2 Years After Acute COVID‐19.” Scientific Reports 13, no. 1: 1–9. 10.1038/s41598-023-36995-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-36995-4</ArticleId><ArticleId IdType="pmc">PMC10336045</ArticleId><ArticleId IdType="pubmed">37433819</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisiel, M. A. , Janols H., Nordqvist T., et al. 2022. “Predictors of Post‐COVID‐19 and the Impact of Persistent Symptoms in Non‐Hospitalized Patients 12 Months After COVID‐19, With a Focus on Work Ability.” Upsala Journal of Medical Sciences 127: 8794. 10.48101/UJMS.V127.8794.</Citation><ArticleIdList><ArticleId IdType="doi">10.48101/UJMS.V127.8794</ArticleId><ArticleId IdType="pmc">PMC9383047</ArticleId><ArticleId IdType="pubmed">35991464</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, J. , Wood J., Jaycox J. R., et al. 2023. “Distinguishing Features of Long COVID Identified Through Immune Profiling.” Nature 623, no. 7985: 139. 10.1038/S41586-023-06651-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41586-023-06651-Y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff, A. L. , and Lipkin W. I.. 2023. “ME/CFS and Long COVID Share Similar Symptoms and Biological Abnormalities: Road Map to the Literature.” Frontiers in Medicine 10: 1187163. 10.3389/FMED.2023.1187163/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FMED.2023.1187163/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC10278546</ArticleId><ArticleId IdType="pubmed">37342500</ArticleId></ArticleIdList></Reference><Reference><Citation>Krupp, L. B. 1989. “The Fatigue Severity Scale. Application to Patients With Multiple Sclerosis and Systemic Lupus Erythematosus.” Archives of Neurology 46, no. 10: 1121–1123. 10.1001/ARCHNEUR.1989.00520460115022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/ARCHNEUR.1989.00520460115022</ArticleId><ArticleId IdType="pubmed">2803071</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig, B. , Deckert M., Krajnc N., et al. 2023. “Reported Neurological Symptoms After Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection: A Systematic Diagnostic Approach.” European Journal of Neurology 30: 2713–2725. 10.1111/ENE.15923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ENE.15923</ArticleId><ArticleId IdType="pubmed">37306533</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin, E. M. , Srowig A., Utech I., et al. 2023. “Persistent Cognitive Slowing in Post‐COVID Patients: Longitudinal Study Over 6 Months.” Journal of Neurology 1: 1–13. 10.1007/S00415-023-12069-3/FIGURES/5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00415-023-12069-3/FIGURES/5</ArticleId><ArticleId IdType="pmc">PMC10769987</ArticleId><ArticleId IdType="pubmed">37936010</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavroudis, I. , Kazis D., Kamal F. Z., et al. 2024. “Understanding Functional Neurological Disorder: Recent Insights and Diagnostic Challenges.” International Journal of Molecular Sciences 25, no. 8: 4470. 10.3390/IJMS25084470.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/IJMS25084470</ArticleId><ArticleId IdType="pmc">PMC11050230</ArticleId><ArticleId IdType="pubmed">38674056</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje, M. , and Iwasaki A.. 2022. “The Neurobiology of Long COVID.” Neuron 110, no. 21: 3484–3496. 10.1016/J.NEURON.2022.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NEURON.2022.10.006</ArticleId><ArticleId IdType="pmc">PMC9537254</ArticleId><ArticleId IdType="pubmed">36288726</ArticleId></ArticleIdList></Reference><Reference><Citation>Morin, C. M. , Belleville G., Bélanger L., and Ivers H.. 2011. “The Insomnia Severity Index: Psychometric Indicators to Detect Insomnia Cases and Evaluate Treatment Response.” Sleep 34, no. 5: 601–608. 10.1093/SLEEP/34.5.601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/SLEEP/34.5.601</ArticleId><ArticleId IdType="pmc">PMC3079939</ArticleId><ArticleId IdType="pubmed">21532953</ArticleId></ArticleIdList></Reference><Reference><Citation>Movsisyan, M. , Chopikyan A., Kasparova I., et al. 2022. “Kinetics of Anti‐Nucleocapsid IgG Response in COVID‐19 Immunocompetent Convalescent Patients.” Scientific Reports 12, no. 1: 12403. 10.1038/S41598-022-16402-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41598-022-16402-0</ArticleId><ArticleId IdType="pmc">PMC9297274</ArticleId><ArticleId IdType="pubmed">35859108</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian, A. , Sehgal K., Gupta A., et al. 2021. “Post‐Acute COVID‐19 Syndrome.” Nature Medicine 27, no. 4: 601–615. 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Nittas, V. , Gao M., West E. A., et al. 2022. “Long COVID Through a Public Health Lens: An Umbrella Review.” Public Health Reviews 43: 1604501. 10.3389/PHRS.2022.1604501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/PHRS.2022.1604501</ArticleId><ArticleId IdType="pmc">PMC8963488</ArticleId><ArticleId IdType="pubmed">35359614</ArticleId></ArticleIdList></Reference><Reference><Citation>Nystad, T. W. , and Myrmel H.. 2007. “Prevalence of Primary Versus Reactivated Epstein‐Barr Virus Infection in Patients With VCA IgG‐, VCA IgM‐ and EBNA‐1‐Antibodies and Suspected Infectious Mononucleosis.” Journal of Clinical Virology 38, no. 4: 292–297. 10.1016/J.JCV.2007.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JCV.2007.01.006</ArticleId><ArticleId IdType="pubmed">17336144</ArticleId></ArticleIdList></Reference><Reference><Citation>
ONS
. 2021. “Technical Article: Updated Estimates of the Prevalence of Post‐Acute Symptoms Among People With Coronavirus (COVID‐19) in the UK—Office for National Statistics.” ONS. Accessed November 10, 2023. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021.</Citation></Reference><Reference><Citation>Peluso, M. J. , Deveau T.‐M., Munter S. E., et al. 2023. “Chronic Viral Coinfections Differentially Affect the Likelihood of Developing Long COVID.” Journal of Clinical Investigation 133, no. 3: e163669. 10.1172/JCI163669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163669</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen, E. L. , Goßling A., Adam G., et al. 2022. “Multi‐Organ Assessment in Mainly Non‐Hospitalized Individuals After SARS‐CoV‐2 Infection: The Hamburg City Health Study COVID Programme.” European Heart Journal 43, no. 11: 1124. 10.1093/EURHEARTJ/EHAB914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/EURHEARTJ/EHAB914</ArticleId><ArticleId IdType="pmc">PMC8755397</ArticleId><ArticleId IdType="pubmed">34999762</ArticleId></ArticleIdList></Reference><Reference><Citation>Rass, V. , Tymoszuk P., Sahanic S., et al. 2023. “Distinct Smell and Taste Disorder Phenotype of Post‐Acute COVID‐19 Sequelae.” European Archives of Oto‐Rhino‐Laryngology 280, no. 11: 5115–5128. 10.1007/S00405-023-08163-X/FIGURES/5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00405-023-08163-X/FIGURES/5</ArticleId><ArticleId IdType="pmc">PMC10562286</ArticleId><ArticleId IdType="pubmed">37670171</ArticleId></ArticleIdList></Reference><Reference><Citation>Salari, N. , Hosseinian‐Far A., Jalali R., et al. 2020. “Prevalence of Stress, Anxiety, Depression Among the General Population During the COVID‐19 Pandemic: A Systematic Review and Meta‐Analysis.” Globalization and Health 16, no. 1: 57. 10.1186/S12992-020-00589-W.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12992-020-00589-W</ArticleId><ArticleId IdType="pmc">PMC7338126</ArticleId><ArticleId IdType="pubmed">32631403</ArticleId></ArticleIdList></Reference><Reference><Citation>Spatola, M. , Nziza N., Jung W., et al. 2023. “Neurologic Sequelae of COVID‐19 Are Determined by Immunologic Imprinting From Previous Coronaviruses.” Brain 146, no. 10: 4292–4305. 10.1093/brain/awad155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awad155</ArticleId><ArticleId IdType="pmc">PMC11004923</ArticleId><ArticleId IdType="pubmed">37161609</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer, R. L. , Kroenke K., and Williams J. B. W.. 1999. “Validation and Utility of a Self‐Report Version of PRIME‐MD: The PHQ Primary Care Study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.” JAMA 282, no. 18: 1737–1744. 10.1001/JAMA.282.18.1737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.282.18.1737</ArticleId><ArticleId IdType="pubmed">10568646</ArticleId></ArticleIdList></Reference><Reference><Citation>Srikanth, S. , Boulos J. R., Dover T., Boccuto L., and Dean D.. 2023. “Identification and Diagnosis of Long COVID‐19: A Scoping Review.” Progress in Biophysics and Molecular Biology 182: 1–7. 10.1016/J.PBIOMOLBIO.2023.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.PBIOMOLBIO.2023.04.008</ArticleId><ArticleId IdType="pmc">PMC10176974</ArticleId><ArticleId IdType="pubmed">37182545</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, Y. , Yuan D., Chen D. G., et al. 2022. “Multiple Early Factors Anticipate Post‐Acute COVID‐19 Sequelae.” Cell 185, no. 5: 881–895.e20. 10.1016/J.CELL.2022.01.014/ATTACHMENT/A9DD3624-454F-43DF-BAC6-50782B7A4E9F/MMC7.XLSX.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELL.2022.01.014/ATTACHMENT/A9DD3624-454F-43DF-BAC6-50782B7A4E9F/MMC7.XLSX</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes, D. L. , Holdsworth L., Jawad N., Gunasekera P., Morice A. H., and Crooks M. G.. 2021. “Post‐COVID‐19 Symptom Burden: What Is Long‐COVID and How Should We Manage It?” Lung 199, no. 2: 113–119. 10.1007/S00408-021-00423-Z/FIGURES/2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00408-021-00423-Z/FIGURES/2</ArticleId><ArticleId IdType="pmc">PMC7875681</ArticleId><ArticleId IdType="pubmed">33569660</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet, M. , Geddes J. R., Husain M., Luciano S., and Harrison P. J.. 2021. “6‐Month Neurological and Psychiatric Outcomes in 236 379 Survivors of COVID‐19: A Retrospective Cohort Study Using Electronic Health Records.” Lancet Psychiatry 8, no. 5: 416–427. 10.1016/s2215-0366(21)00084-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet, M. , Sillett R., Zhu L., et al. 2022. “Neurological and Psychiatric Risk Trajectories After SARS‐CoV‐2 Infection: An Analysis of 2‐Year Retrospective Cohort Studies Including 1 284 437 Patients.” Lancet Psychiatry 9, no. 10: 815–827. 10.1016/S2215-0366(22)00260-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(22)00260-7</ArticleId><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>
Team Data
. 2024. “DATATab: Online Statistics Calculator: DATAtab e.U. DATATab: Online Statistics Calculator: DATAtab e.U.” Team Data. Accessed August 20, 2024. https://datatab.de/.</Citation></Reference><Reference><Citation>Teodoro, T. , Chen J., Gelauff J., and Edwards M. J.. 2023. “Functional Neurological Disorder in People With Long COVID: A Systematic Review.” European Journal of Neurology 30: 1505–1514. 10.1111/ENE.15721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ENE.15721</ArticleId><ArticleId IdType="pubmed">36719069</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlgren, C. , Forsberg G., Divanoglou A., et al. 2023. “Two‐Year Follow‐Up of Patients With Post‐COVID‐19 Condition in Sweden: A Prospective Cohort Study.” Lancet Regional Health—Europe 28: 100595. 10.1016/j.lanepe.2023.100595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100595</ArticleId><ArticleId IdType="pmc">PMC9951394</ArticleId><ArticleId IdType="pubmed">36855599</ArticleId></ArticleIdList></Reference><Reference><Citation>West, E. A. , Anker D., Amati R., et al. 2020. “Corona Immunitas: Study Protocol of a Nationwide Program of SARS‐CoV‐2 Seroprevalence and Seroepidemiologic Studies in Switzerland.” International Journal of Public Health 65, no. 9: 1529–1548. 10.1007/S00038-020-01494-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00038-020-01494-0</ArticleId><ArticleId IdType="pmc">PMC7584867</ArticleId><ArticleId IdType="pubmed">33098441</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization
. 2022. “Post COVID‐19 Condition (Long COVID).”. Accessed October 17, 2023. https://www.who.int/europe/news‐room/fact‐sheets/item/post‐covid‐19‐condition.</Citation></Reference><Reference><Citation>Xu, E. , Xie Y., and Al‐Aly Z.. 2022. “Long‐Term Neurologic Outcomes of COVID‐19.” Nature Medicine 28, no. 11: 2406–2415. 10.1038/s41591-022-02001-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02001-z</ArticleId><ArticleId IdType="pmc">PMC9671811</ArticleId><ArticleId IdType="pubmed">36138154</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>